| Literature DB >> 26802086 |
Mireia Valles-Colomer1, Youssef Darzi2, Sara Vieira-Silva1, Gwen Falony1, Jeroen Raes1, Marie Joossens2.
Abstract
Meta-omics [metagenomics, metatranscriptomics, and metaproteomics] are rapidly expanding our knowledge of the gut microbiota in health and disease. These technologies are increasingly used in inflammatory bowel disease [IBD] research. Yet, meta-omics data analysis, interpretation, and among-study comparison remain challenging. In this review we discuss the role these techniques are playing in IBD research, highlighting their strengths and limitations. We give guidelines on proper sample collection and preparation methods, and on performing the analyses and interpreting the results, reporting available user-friendly tools and pipelines. © European Crohn’s and Colitis Organistion (ECCO) 2016.Entities:
Keywords: 16S; Metagenomics; meta-omics; metaproteomics; metatranscriptomics; microbiota
Mesh:
Substances:
Year: 2016 PMID: 26802086 DOI: 10.1093/ecco-jcc/jjw024
Source DB: PubMed Journal: J Crohns Colitis ISSN: 1873-9946 Impact factor: 9.071